Biffi, Annalisa
,
Scotti, Lorenza
Rea, Federico
Lucenteforte, Ersilia
Chinellato, Alessandro
Vetrano, Davide L.
Vitale, Cristiana
Agabiti, Nera
Sultana, Janet
Roberto, Giuseppe
Mugelli, Alessandro
Corrao, Giovanni
Funding for this research was provided by:
AIFA - the Italian Medicines Agency, Rome, Italy (Project AIFA-FARM9LBBBL)
Article History
First Online: 27 March 2018
Compliance with ethical standards
:
: This study was funded by a research grant from the AIFA—the Italian Medicines Agency—(AIFA, project AIFA-FARM9LBBBL), Rome, Italy. Data analyses were performed at the Laboratory of Healthcare Research & Pharmacoepidemiology, University of Milano-Bicocca with grants from the Italian Ministry of Education, University and Research (’Fondo d’Ateneo per la Ricerca’ portion, year 2015).
: EL received research support from the Italian Agency of Drug (AIFA). AM received research support from the Italian Agency of Drug (AIFA), the Italian Ministry for University and Research (MIUR), Gilead, and Menarini. In the last two years he received personal fees as speaker/consultant from Menarini Group, IBSA, Molteni, Angelini and Pfizer Alliance. GC received research support from the European Community (EC), the Italian Agency of Drug (AIFA), and the Italian Ministry for University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e., Novartis, GSK, Roche, AMGEN and BMS). He also received honoraria as member of Advisory Board from Roche. AC received support for participation at pharmacological meetings (SIF) and honoraria as member of Advisory board on biological drugs. Other authors declare that they have no conflict of interest to disclose.